Maria Frank-Kamenetsky

Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms

Akin Akinc, William Querbes, Soma De et al. · Molecular Therapy · 2010 · 1.2K citations · Full text

Pharmacy, Molecular Pharmaceutics, Pharmaceutics +17

From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus

Alanna Strong, Maria Frank-Kamenetsky, Noemi E Lee et al. · Nature · 2010 · 1.2K citations · Full text

Life Sciences, Genetics, Molecular Genetics +10

Lipid-like materials for low-dose, in vivo gene silencing

Kevin T. Love, Kerry P. Mahon, Christopher G. Levins et al. · Proceedings of the National Academy of Sciences · 2010 · 965 citations · Full text

Pharmacy, Molecular Pharmaceutics, Pharmaceutics +17

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Maria Frank-Kamenetsky, Aldo Grefhorst, Norma N. Anderson et al. · Proceedings of the National Academy of Sciences · 2008 · 639 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya et al. · The Lancet · 2013 · 574 citations

Life Sciences, Biochemistry, Pharmacology +16